EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Minireview: Challenges and Opportunities in Development of PPAR Agonists

Matthew B Wright, Michele Bortolini, Moh Tadayyon, Martin Bopst

Molecular Endocrinology · 01.11.2014 · 28 (11) · 1756-1768

DOI: 10.1210/me.2013-1427 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Endocrinology, erschienen am 01.11.2014. Verfasst von Matthew B Wright und 3 weiteren Autor:innen. Beteiligte Einrichtung: F. Hoffmann-La Roche Pharmaceuticals (M.B.W., M.Bor., M.Bop.), CH-4070 Basel, Switzerland; and MediTech Media (M.T.), London EC1V 9AZ, United Kingdom. Die Arbeit wurde bisher 159-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical impact of the fibrate and thiazolidinedione drugs on dyslipidemia and diabetes is driven mainly through activation of two transcription factors, peroxisome proliferator-activated receptors (PPAR)-α and PPAR-γ. However, substantial differences exist in the therapeutic and side-effect profiles of specific drugs. This has been attributed primarily to the complexity of drug-target complexes that involve many coregulatory proteins in the context of specific target gene promoters. Recent data have revealed that some PPAR ligands interact with other non-PPAR targets. Here we review concepts used to develop new agents that preferentially modulate transcriptional complex assembly, target more than one PPAR receptor simultaneously, or act as partial agonists. We highlight newly described on-target mechanisms of PPAR regulation including phosphorylation and nongenomic regulation. We briefly describe the recently discovered non-PPAR protein targets of thiazolidinediones, mitoNEET, and mTOT. Finally, we summarize the contributions of on- and off-target actions to select therapeutic and side effects of PPAR ligands including insulin sensitivity, cardiovascular actions, inflammation, and carcinogenicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnimalsDiabetes Mellitus, Type 2DyslipidemiasHumansHypoglycemic AgentsLignansPeroxisome Proliferator-Activated ReceptorsThiazolidinediones

Substanzen

Hypoglycemic AgentsLignansPeroxisome Proliferator-Activated ReceptorsThiazolidinediones

Autor:innen und Institutionen

  • F. Hoffmann-La Roche Pharmaceuticals (M.B.W., M.Bor., M.Bop.), CH-4070 Basel, Switzerland; and MediTech Media (M.T.), London EC1V 9AZ, United Kingdom.

Zitieren

APA

Wright, M. B., Bortolini, M., Tadayyon, M., & Bopst, M. (2014). Minireview: Challenges and Opportunities in Development of PPAR Agonists. Molecular Endocrinology, 28(11), 1756-1768. https://doi.org/10.1210/me.2013-1427

Vancouver

Wright MB, Bortolini M, Tadayyon M, Bopst M. Minireview: Challenges and Opportunities in Development of PPAR Agonists. Molecular Endocrinology. 2014;28(11):1756-1768. doi:10.1210/me.2013-1427

BibTeX
@article{Wright2014,
  author = {Wright, Matthew B and Bortolini, Michele and Tadayyon, Moh and Bopst, Martin},
  title = {Minireview: Challenges and Opportunities in Development of PPAR Agonists},
  journal = {Molecular Endocrinology},
  year = {2014},
  volume = {28},
  number = {11},
  pages = {1756--1768},
  doi = {10.1210/me.2013-1427}
}
Kostenlos starten →